nangibotide

Phase 2Peptide

IInotrem

nangibotide is one of 44 small molecule programs targeting Septic Shock. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Septic ShockActive, not recruiting

Septic ShockPhase 2

Active, not recruiting

Competition

Competitive Landscape

72 competitors in Septic Shock

#DrugCompanyPhaseTrials

Primacor

Sanofi

Approved

2 2

Glypressin

MMallinckrodt

Approved

11 3

Versed

CConrado Roberto Hoffmann Filho

Approved

4 4

Ketalar

AAultman Health Foundation

Approved

3 5

Florinef

Jazz Pharmaceuticals

Phase 3

4 6

Cyklokapron

JJ Molner

Approved

—7

Methylthioninium Chloride

PProvepharm SAS

Phase 3

10 8

Brevibloc

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

9 9

Rapiblyk

AAultman Health Foundation

Phase 3

1 10

Hydrocortisone Sodium Succinate

NNational Cancer Institute (NCI)

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Septic Shock2 trials

Efficacy, Safety and Tolerability of Nangibotide in Patients With Septic Shock

Active, not recruiting·IInotrem·Phase 2·NCT04055909·355 enrolled

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of 3 Doses of MOTREM (Nangibotide) in Patients With Septic Shock

Completed·IInotrem·Phase 2·NCT03158948·50 enrolled

COVID-191 trial

Efficacy and Safety Study of Nangibotide in Patients With COVID-19 Receiving Ventilatory Support

Completed·IInotrem·Phase 2·NCT04429334·220 enrolled

Unspecified1 trial

Safety, Tolerability and Pharmacokinetic Profiles of MOTREM (LR12) in Healthy Male Subjects

Completed·IInotrem·Phase 1·NCT03463044·27 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for nangibotide. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — nangibotide compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for nangibotide. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Inotrem company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Peptide[2]
Highest Phase: Phase 2[1]
Company: IInotrem

nangibotide

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Septic Shock2 trials

COVID-191 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News